Enhanced Inhibition of Dipeptide Repeat Proteins

Publication ID: 24-11857534_0001_PTD

Published: October 28, 2025

Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Inhibition of Dipeptide Repeat Proteins,” Published Technical Disclosure No. 24-11857534_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857534_0001_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,534.

Summary of the Inventive Concept

This invention relates to novel methods and systems for treating neurodegenerative diseases associated with dipeptide repeat proteins, focusing on enhancing the efficacy and delivery of Type I PRMT inhibitors.

Background and Problem Solved

The original patent disclosed the use of Type I PRMT inhibitors to decrease cellular toxicity caused by dipeptide repeat proteins. However, the existing approach has limitations, including suboptimal efficacy, inadequate delivery across the blood-brain barrier, and lack of combination therapies. The new inventive concept addresses these limitations by introducing secondary agents, gene therapies, and nanoparticle carriers to improve the treatment of neurodegenerative diseases.

Detailed Description of the Inventive Concept

The new claims introduce a system comprising a Type I PRMT inhibitor and a secondary agent that enhances the inhibitor's efficacy, such as antioxidants, anti-inflammatory agents, or neuroprotective compounds. Another embodiment involves administering a Type I PRMT inhibitor in combination with a gene therapy that reduces the expression of the C9ORF72 gene, thereby reducing the formation of toxic dipeptide repeat proteins. Additionally, the invention includes a composition of matter featuring a Type I PRMT inhibitor and a nanoparticle carrier that facilitates the inhibitor's delivery across the blood-brain barrier. The inventive concept also encompasses methods for diagnosing and monitoring neurodegenerative diseases associated with dipeptide repeat proteins.

Novelty and Inventive Step

The new claims introduce novel combinations of Type I PRMT inhibitors with secondary agents, gene therapies, and nanoparticle carriers, which provide a significant enhancement in efficacy and delivery compared to the original patent. The inventive concept's novelty lies in the synergistic effects achieved by these combinations, which overcome the limitations of the existing approach.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different types of secondary agents, gene therapies, or nanoparticle carriers. Additionally, the inventive concept could be adapted for treating other neurodegenerative diseases or disorders associated with dipeptide repeat proteins.

Potential Commercial Applications and Market

The enhanced inhibition of dipeptide repeat proteins has significant commercial potential in the treatment of neurodegenerative diseases, such as ALS and FTD. The target market includes pharmaceutical companies, biotechnology firms, and research institutions focused on developing novel therapeutics for these diseases.

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Neurodegenerative disease treatment, specifically focusing on molecular interventions for ALS and FTD involving dipeptide repeat protein (DRP) inhibition, requiring expertise in molecular biology, pharmacology, and neurological therapeutics

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology or neuroscience, familiar with protein modification techniques, gene therapy approaches, and pharmaceutical intervention strategies for neurodegenerative disorders

Obviousness Rationale

A person having ordinary skill would recognize that enhancing DRP inhibition requires exploring complementary intervention strategies such as secondary agents, targeted gene therapies, and improved delivery mechanisms. The source patent establishes the foundational concept of Type I PRMT inhibition for DRP toxicity, making subsequent combinatorial approaches a predictable extension of the original therapeutic strategy. The PTD's variations represent logical incremental improvements that would be apparent to a skilled practitioner seeking to optimize neurological disease treatment.

Obvious Combinations & Variations

Source Patent Element

Type I PRMT inhibitor for decreasing cellular toxicity caused by dipeptide repeat proteins

PTD Variation

Combining Type I PRMT inhibitor with secondary agents like antioxidants or anti-inflammatory compounds

Obviousness Reasoning

Combining therapeutic agents with complementary mechanisms is a standard approach in pharmaceutical development, representing a predictable solution for enhancing treatment efficacy

Source Patent Element

Inhibition of DRPs generated by C9ORF72 gene expansion

PTD Variation

Gene therapy approach to reduce C9ORF72 gene expression concurrent with PRMT inhibition

Obviousness Reasoning

Targeting multiple molecular pathways is a known strategy in complex disease intervention, representing a finite set of logical therapeutic approaches

Source Patent Element

Method of treating neurological disorders involving dipeptide repeat proteins

PTD Variation

Nanoparticle carrier system for improved blood-brain barrier penetration of PRMT inhibitors

Obviousness Reasoning

Developing advanced drug delivery mechanisms is a standard technique for improving pharmaceutical bioavailability, particularly for neurological treatments

Source Patent Element

DRPs comprising asymmetrically dimethylated arginine-based peptides

PTD Variation

Diagnostic method detecting asymmetrically dimethylated DRPs using immunoassay or mass spectrometry

Obviousness Reasoning

Developing diagnostic techniques based on existing molecular markers represents a predictable extension of scientific understanding in disease characterization

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857534, the variations disclosed herein would be considered obvious to a person having ordinary skill in the art of neurological disease treatment. The incremental modifications represent predictable combinations of known techniques for inhibiting dipeptide repeat protein toxicity, utilizing standard pharmaceutical development strategies that would be apparent to a skilled practitioner in the field.

Original Patent Information

Patent Number	US 11,857,534
Title	Inhibition of dipeptide repeat proteins
Assignee(s)	ALS Therapy Development Institute